Condition: Hematological Malignancies · Graft-versus-Host Disease (GVHD) · Sponsor: University of Nebraska
This study will compare post-transplant health-related quality of life following the use of standard versus attenuated dose of post-transplant cyclophosphamide in addition to two-drug graft-versus-host disease (GVHD) prophylaxis among recipients of allogeneic hematopoietic stem cell transplant.
This description comes directly from the study's public registry record.
Taylor Johnson · 402-559-4596 · taylora.johnson@unmc.edu
IIT OFFICE · 402-559-4596 · iitoffice@unmc.edu
Always discuss trial participation with your own doctor first.
| University of Nebraska Medical Center | Omaha, Nebraska, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06799195